Over the past two months, CRCM teams have been engaged in intense scientific activity, as evidenced by numerous publications in leading international journals.

This work demonstrates the diversity of the center’s expertise, the quality of its collaborations, and the constant commitment of its researchers to advancing our understanding of cancer mechanisms and developing new therapeutic approaches.

Below is a list of all CRCM scientific publications released during this period.

OHIO Department

Nunès / Devillier team

Factors Associated With Toxicity of FOLFIRINOX in Elderly Patients With Pancreatic Ductal Adenocarcinoma.

Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic cancer.

Immediate variations in high-dimensional circulating immune cells following pancreatectomy.

Pathophysiological rationale and management of anxio-depressive syndrome among cancer patients.

Chames team

Junctional adhesion molecule-C: A multifunctional mediator of cell adhesion.

Translate-it Department

Dusetti / Iovanna team

Factors Associated With Toxicity of FOLFIRINOX in Elderly Patients With Pancreatic Ductal Adenocarcinoma.

Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic cancer.

Evaluating the therapeutic role of salvianolic acid A on pancreatic cancer cells through interaction with the intrinsically disordered protein NUPR1.

Synergistic antitumor activity of sorafenib and the NUPR1 inhibitor LZX-2-73 in multiple cancer models.

Benzekry / Ciccolini team

Predicting the toxicity-efficacy ratio of venetoclax in real-world patients.

Clinical oncology pharmacy: French current situation of pharmaceutical interventions in production units in 2024.

Mamessier / Bertucci team

The plasma nanoDSF denaturation profiles predict the presence of breast cancer.

Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2.

Pasquier / André team

Chemotherapy-free cancer treatment – not for everyone yet.

Pharmacokinetic-Based Dose Adjustment of Selumetinib in 2 Young Children With Neurofibroma.

Genome integrity department

Lachaud team

Alkyne modification of DNA cross-linking antitumor agent SJG-136 to monitor induced lesions in cells by click chemistry.

Coulon team

Tel1 is recruited at chromosomal loop/axis contact sites to modulate meiotic DNA double-strand breaks interference.

Llorente team

Tel1 is recruited at chromosomal loop/axis contact sites to modulate meiotic DNA double-strand breaks interference.

COMET Department

Vasseur / Tomasini team

The extracellular matrix drives guanylate production and protects pancreatic cancer cells from oxaliplatin-induced DNA damage.

Borg / Maina team

MOVIE phase II trial of tremelimumab plus durvalumab combined with metronomic oral vinorelbine in patients with head and neck cancer.

Charafe / Ginestier team

Injury and inflammation promote cancer progression at the anorectal junction.